Statements (86)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
gptkb:SS |
| gptkbp:approved_for_use |
gptkb:FDA
|
| gptkbp:approves |
gptkb:FDA
gptkb:United_States Adults |
| gptkbp:atccode |
A10 BK03
A10 BK01 |
| gptkbp:bioavailability |
78%
|
| gptkbp:brand |
gptkb:Farxiga
|
| gptkbp:can_be_combined_with |
gptkb:Metformin
gptkb:Dulaglutide |
| gptkbp:casnumber |
461432-26-8
|
| gptkbp:category |
gptkb:C
|
| gptkbp:chemical_formula |
C21 H25 Cl O6 S
C21 H25 Na O6 S C21 H25 Na O8 S |
| gptkbp:class |
gptkb:SS
antidiabetic agent |
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:clinical_use |
glycemic control
|
| gptkbp:contraindication |
Severe renal impairment
severe renal impairment |
| gptkbp:developed_by |
gptkb:Astra_Zeneca
|
| gptkbp:dosage_form |
gptkb:tablet
10 mg 5 mg |
| gptkbp:effective_date |
gptkb:2014
|
| gptkbp:excretion |
Urine
urine |
| gptkbp:formulation |
gptkb:Dapagliflozin/_Glimepiride
gptkb:Dapagliflozin/_Metformin gptkb:Dapagliflozin/_Metformin/_NPH gptkb:Dapagliflozin/_Metformin/_Saxagliptin gptkb:Dapagliflozin/_Metformin/_Sitagliptin gptkb:Dapagliflozin/_Saxagliptin oral tablet Dapagliflozin/ Canagliflozin Dapagliflozin/ Empagliflozin Dapagliflozin/ Metformin/ Canagliflozin Dapagliflozin/ Metformin/ Detemir Dapagliflozin/ Metformin/ Dulaglutide Dapagliflozin/ Metformin/ Empagliflozin Dapagliflozin/ Metformin/ Exenatide Dapagliflozin/ Metformin/ Glargine Dapagliflozin/ Metformin/ Glimepiride Dapagliflozin/ Metformin/ Insulin Dapagliflozin/ Metformin/ Insulin aspart Dapagliflozin/ Metformin/ Insulin degludec Dapagliflozin/ Metformin/ Insulin detemir Dapagliflozin/ Metformin/ Insulin glargine Dapagliflozin/ Metformin/ Insulin glulisine Dapagliflozin/ Metformin/ Insulin lispro Dapagliflozin/ Metformin/ Liraglutide Dapagliflozin/ Metformin/ Pramlintide Dapagliflozin/ Metformin/ Regular insulin |
| gptkbp:healthcare |
gptkb:2014
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dapagliflozin
|
| gptkbp:indication |
heart failure
chronic kidney disease glycemic control |
| gptkbp:interacts_with |
gptkb:diabetes
Diuretics diuretics sulfonylureas |
| gptkbp:lifespan |
12.9 hours
|
| gptkbp:marketed_as |
gptkb:Astra_Zeneca
gptkb:Forxiga |
| gptkbp:mechanism_of_action |
gptkb:SS
inhibits sodium-glucose co-transporter 2 Inhibits SGLT2 |
| gptkbp:metabolism |
glucuronidation
|
| gptkbp:route_of_administration |
Oral
oral |
| gptkbp:side_effect |
dehydration
Urinary tract infections hypoglycemia urinary tract infection thirst urinary tract infections genital mycotic infections Genital mycotic infections |
| gptkbp:used_for |
Type 2 diabetes
type 2 diabetes |
| gptkbp:bfsParent |
gptkb:Astra_Zeneca
|
| gptkbp:bfsLayer |
4
|